Understanding Communication and Cognitive Impairments in Neurodegenerative Disorders

Study Purpose:

The goal is to improve the fundamental knowledge about articulatory motor performance in people with Lou Gehrig's disease (also known as ALS) and Parkinson's disease (PD), in order to develop more sensitive assessments for progressive speech loss, which may lead to the improved timing of speech therapies.


Amyotrophic Lateral Sclerosis (ALS),  Familial ALS,  Sporadic ALS, Healthy Volunteer, Parkinson Disease

Study Type:

Interventional Trial

Study Category:


Study Status:

Not enrolling


Not Applicable

Study Chair(s)/Principal Investigator(s):

Mili Kuruvilla-Dugdale, PhD, University of Missouri-Columbia

Clinicaltrials.gov ID (11 digit #):


Neals Affiliated?


Coordinating Center Contact Information

University of Missouri-Columbia
Mili Kuruvilla-Dugdale / .(JavaScript must be enabled to view this email address) / 573-882-2910
.(JavaScript must be enabled to view this email address) Columbia, Missouri 65211 United States

Full Study Summary:

The long-term goal is to optimize dysarthria assessment by improving the early detection and tracking of articulatory performance in progressive dysarthrias. The short-term goal of the proposed cross-sectional study is to focus on ALS and PD and quantify articulatory kinematic performance as a function of phonetic complexity, which is experimentally manipulated based on theoretical principles of speech motor development. The research strategy is to use 3D electromagnetic articulography to examine phonetic complexity effects of single word stimuli at the articulatory kinematic level in 15 talkers each with preclinical, mild, and moderate dysarthria, relative to 45 controls. The central hypothesis is that as dysarthria severity increases the discrepancy in articulatory performance, indexed by movement speed, distance, coordination, and variability, between people with dysarthria and typical controls will significantly increase at a lower phonetic complexity level.

Study Sponsor:

University of Missouri-Columbia

Participant Duration:

Estimated Enrollment:


Estimated Study Start Date:


Estimated Study Completion Date:


Posting Last Modified Date:


Date Study Added to alsconsortium.org:

  • Eligibility Criteria


    Female, Male

    Minimum Age:


    Maximum Age:


    Time since Symptom Onset:


    Time since Diagnosis:


    Can participants use Riluzole?


    Inclusion Criteria:

    May or may not have a neurological impairment.
    Age range of 19-90 years.
    Male or female.
    Provide written consent before any study specific procedures are performed.
    Have ability to comply with basic instructions.
    Monolingual English speaker.
    Have ability to partake in a 90 minute data collection.

    Exclusion Criteria:

    Any speech, language, cognition, or hearing impairment prior to diagnosis of a neurodegenerative disease.
    Anyone not appropriate for study participation, as deemed by the principal investigator.

  • Site Contact Information

    University of Kansas Medical Center
    Mili Kuruvilla / .(JavaScript must be enabled to view this email address) / 573-882-2910
    Fairway, Kansas 66205
    United States

    University of Missouri-Columbia
    Mili Kuruvilla / .(JavaScript must be enabled to view this email address) / 573-882-2910
    Columbia, Missouri 65211
    United States